McKesson recalls Xanax blister packs with blank labels


McKesson Packaging Services is recalling blister packs of Xanax and a stomach drug because of labeling problems.

According to the most recent FDA Enforcement Report, McKesson is recalling 34,920 blister cards because the primary packaging label contains no product information--no product name, strength info, lot number or expiration date. The product was manufactured by Sandoz but packaged by McKesson’s North Carolina-based packaging operation and distributed in Colorado, Illinois, Louisiana and Ohio.

Additionally, the company is recalling 1,810 blister packs of the proton pump inhibitor Lansoprazole manufactured by Dr. Reddy’s Laboratories ($RDY) that were shipped nationwide. In that case, the blister packs' outer secondary packaging was mislabeled as 30-mg tablets instead of 40-mg tablets. The inner packaging is properly labeled, the report says.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Both voluntary recalls were issued this month.

The San Francisco-based drug wholesaling giant has been dealing with a variety of issues this year. In January it acknowledged it had eliminated 1,600 jobs, about 4% of its workforce. That announcement came after the company reduced its forecast for the fiscal year as generic pricing pressure and industry consolidation took a toll.

More recently, McKesson’s German distributor was raided by Germany’s Cartel Office a couple of weeks ago. Gehe was one of a number of wholesalers from which authorities reportedly seized documents as part of a probe into possible price collusion.  

- access the recall here

Related Articles:
Drug distributor McKesson laying off 1,600 
McKesson's German unit raided in price collusion probe


Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.